Építés alatt – nem éles oldal
Belépés
Résztvevőt keres1/2. fázis

Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)

A legfontosabb adatok

Ki végzi
Shanghai Mianyi Biopharmaceutical Co., Ltd.
Hol
Kína4 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
1/2. fázis
Résztvevők
60 fő, tervezett
Kezdés
2026. aug. 26.
Várható befejezés
2029. dec. 30.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • BBM-C101
A regiszteradat frissítve
2026. november 16.

Ki vehet részt

Életkor
18 év – 55 év
Nem
Csak nők
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Ki vehet részt

  • Histologically confirmed HPV16 and/or HPV18 associated HSIL
  • Colposcopy findings at screening at each study center must meet all of the following conditions: The colposcopy examination should be satisfactory and The ECC result must be negative
  • Women of childbearing potential must agree to use highly effective contraception together with their partner throughout the study and for at least 1 year after the first dose ; f and a serum pregnancy test within 7 days prior to enrollment must be negative
  • Willing to voluntarily participate in the study and provide written informed consent
  • In the opinion of the Investigator, the participant is expected to demonstrate good compliance and be able to complete all scheduled visits and follow-up assessments in accordance with the study protocol ; -

Ki nem vehet részt

  • Participants who have received any treatment for HPV positivity or cervical HSIL prior to study drug
  • History of previous therapeutic HPV vaccination ( except for the licensed prophylactic HPV vaccines )
  • Participants who have used any local or systemic immunosuppressive agents prior to the first administration of BBM-C101 injection
  • Received any licensed vaccines within 2 weeks prior to study drug administration
  • Having participated in other clinical trials before signing the informed consent form, including studies involving investigational drugs or devices
  • Participants who have received any gene therapy treatment prior to screening, or plans to receive any other gene therapy treatment during the study period
  • Participants with unstable cardiovascular or cerebrovascular diseases, defined as clinical cardiovascular event (such as unstable angina, myocardial infarction, stroke, etc.) occurring within 3 months prior to screening; participants with severe uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg)
  • Active drug or alcohol use or dependence that, in the opinion of the Investigator, would interfere with adherence to study requirements
  • Major surgery or significant trauma within 4 weeks prior to the first dose
  • Participants with acute cervical inflammation or acute exacerbation of chronic cervical disease
  • Positive results were obtained in the tests for hepatitis C virus antibody, human immunodeficiency virus (HIV)
  • Participants with a history or diagnosis of autoimmune diseases, including but not limited to Crohn's disease, ulcerative colitis, systemic lupus erythematosus, sarcoidosis, Wegener's granulomatosis, Graves' disease, rheumatoid arthritis, hypophysitis , uveitis, autoimmune hepatitis, systemic sclerosis, autoimmune vasculitis, autoimmune neuropathy (Guillain-Barré syndrome), etc
  • Participants with active infections requiring systemic anti-infective therapy
  • Participants with a known history of malignant tumors in any organ/system (regardless of evidence of local recurrence or metastasis)
  • Participants with a history of severe allergic diseases ( e.g., allergy-related shock, dyspnea, angioedema) )
  • Any other conditions judged by the Investigator that may affect a participant's safety or compliance ; -
  • Participants with clinically significant abnormal values in laboratory tests during screening, as determined by the Investigator to increase risk to the participant's participation in the clinical trial . This includes, but is not limited to, any of the following:; White blood cell count < 3.0 × 10⁹/L; Hemoglobin < 90 g/L; Platelet < 100 × 10⁹/L; Aspartate aminotransferase or alanine aminotransferase > 2 × upper limit of normal (ULN); Total bilirubin > 1.5 × ULN; Creatinine > 1.5 × ULN
  • During screening, cytological or histopathological shows any of the following results: adenocarcinoma in situ (AIS), atypical glandular cells-favor neoplasia (AGC-FN), or invasive carcinoma
  • Participants who are unable or unwilling to undergo colposcopy, or have contraindications to colposcopy
  • Pregnant or breastfeeding (lactating)

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 55 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Kína.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this study is to learn about the safety, tolerability, immunogenicity and preliminary efficacy of BBM-C101 injection in patients with High-Grade Squamous Intraepithelial Lesion of the cervix.

A teljes eredeti leírásKevesebb

This study include two phases: Phase I and Phase IIa .

A vizsgálat csoportja

  • Arm of BBM-C101A vizsgált kezelés

    Kezelés: BBM-C101

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase I/ IIa, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesions.
Kérdések a feltételekről
Forrás: NCT07668960: ki vehet részt
A regiszteradat frissítve
2026. november 16.